Compare Enveric Biosciences Inc (ENVB) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Fox Corp Class B — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Fox Corp Class B trades at $56.88 (market cap $24.97B). The key difference: Fox Corp Class B is far larger — about 3732.4× Enveric Biosciences Inc's market cap, and Fox Corp Class B pays a 1.04% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Fox Corp Class B for 75 Days on average.
| ENVB | FOX | |
|---|---|---|
Market Cap | $6.69M | $24.97B |
Volume | 41,141 | 643,221 |
Sector | Health | Media |
52-Week High | $10.80 | $67.76 |
52-Week Low | $1.27 | $44.39 |
Typical Hold Time | 14 Days | 75 Days |
Enterprise Value | -$1.60M | $28.33B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
FOX trades at $56.97, up 2.5% today, with a bearish technical signal but strong fundamentals including a P/E of 14.59 and net income margin of 9.84%. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 highlight operational strength, while cash flow improved to $1.03B in 2025. The stock faces resistance near $57 with support at $55.
The outlook is mixed: analyst consensus targets $84.75 (49% upside) with 42% buy ratings, but technical indicators and projected 2026 earnings decline pose risks. Key opportunities include valuation discount and dividend yield; risks involve earnings volatility and competitive pressures in media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
